Literature DB >> 2421208

Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments.

L S Forno, L A Sternberger, N H Sternberger, A M Strefling, K Swanson, L F Eng.   

Abstract

The reaction of Lewy bodies in the substantia nigra and the sympathetic ganglia was studied in 10 cases of Parkinson's disease and other Lewy body-related conditions, using monoclonal antibodies to non-phosphorylated (02-40) and phosphorylated (03-44 and 07-5) neurofilaments. Although many Lewy bodies were unstained, a peripheral ring of positive immunoreactivity was frequently observed. This reaction was more common and more intense with antibodies to phosphorylated neurofilaments, suggesting a posttranslational phosphorylation of elements in the Lewy body. Although Lewy bodies appear to have some antigenic sites in common with neurofilaments, certain differences between neurofilaments and Lewy body filaments are emphasized.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421208     DOI: 10.1016/0304-3940(86)90337-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  36 in total

1.  Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation.

Authors:  B S Li; L Zhang; J Gu; N D Amin; H C Pant
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material.

Authors:  B Lach; D Grimes; B Benoit; A Minkiewicz-Janda
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Relationships between Lewy bodies and pale bodies in Parkinson's disease.

Authors:  G E Dale; A Probst; P Luthert; J Martin; B H Anderton; P N Leigh
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

4.  Filaments of Lewy bodies contain insoluble cytoskeletal elements.

Authors:  P G Galloway; P Mulvihill; G Perry
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

5.  Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells.

Authors:  G Sobue; Y Hashizume; T Yasuda; E Mukai; T Kumagai; T Mitsuma; J Q Trojanowski
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  Ubiquitin and phosphorylated neurofilament epitopes in ballooned neurons of the extraocular muscle nuclei in a case of Werdnig-Hoffmann disease.

Authors:  S Kato; A Hirano
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

7.  Ca2+/calmodulin-dependent protein kinase II immunoreactivity in Lewy bodies.

Authors:  T Iwatsubo; I Nakano; K Fukunaga; E Miyamoto
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 8.  Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration.

Authors:  Rodolphe Perrot; Raphael Berges; Arnaud Bocquet; Joel Eyer
Journal:  Mol Neurobiol       Date:  2008-07-23       Impact factor: 5.590

9.  Silencing synuclein at the synapse with PLK2.

Authors:  Brendan D Looyenga; Patrik Brundin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-26       Impact factor: 11.205

10.  Mallory body filaments become insoluble after normal assembly into intermediate filaments.

Authors:  M S Pollanen; P Markiewicz; L Weyer; M C Goh; C Bergeron
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.